secwatch.observer — SEC 8-K summary
======================================

Issuer:     InspireMD, Inc. (NSPR)
CIK:        0001433607
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001641172-25-022159
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InspireMD Q2 net loss widens to $13.2M ($0.26/share); revenue up 2.3% to $1.78M
-------------------------------------------------------------------------------

- Net loss of $13.2M ($0.26 per share) vs $7.9M loss ($0.22) in Q2 2024; operating expenses surged 55% to $13.3M.
- Revenue of $1.78M, up 2.3% YoY; gross profit fell 5.4% to $313k; cash & securities dropped to $19.4M from $34.6M.
- Company raised $58M in gross proceeds from equity private placement and warrant exercise.
- FDA granted PMA approval for CGuard Prime carotid stent; US commercial launch commenced; CE Mark under MDR also received.
- Appointed Mike Lawless as CFO and added Raymond W. Cohen to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1433607/000164117225022159/0001641172-25-022159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1433607/000164117225022159/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-022159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer